Bio Therapeutic Drugs Company Investment Opportunity in Milan, Italy
Biotech firm focused on cancer immuno personalized therapy and exosomes for medical and cosmetic applications.
Premium Plan
| Established | 5-10 year(s) |
| Employees | 2 - 5 |
| Legal Entity | Limited Liability Company (LLC) |
| Reported Sales | USD 500 thousand |
| Run Rate Sales | USD 315 thousand |
| EBITDA Margin | 35 % |
| Industries | Bio Therapeutic Drugs |
| Locations | Milan |
| Local Time | 5:31 AM Europe / Rome |
| Listed By | Business Owner / Director |
| Status | Active |
Partial Stake Sale
USD
1.57 million
for
25.0%
stake
(Native Currency: EUR 1,500,000)
Reason: Seeking investment for market expansion and moving into an own trial setting.
The valuation is base...
View More
Includes physical assets worth
USD
142 thousand
Interested to connect with advisors
Name, Phone, Email
Available after connect
Business Name
Available after connect
User Verification
Business Overview
- A biotech firm based in Milan, focusing on cancer immuno personalized therapy.
- Has a portfolio of R&D projects and two Finished Dosage Forms (FDF) in the Italian market, including Aripiprazole and Emtricitabine + Tenofovir.
- The company specializes in the development of microfluidic technology for the production and purification of Exosomes, with applications in anti-inflammatory, skin regenerative, anti-acne and atopic dermatitis, scalp rejuvenation, and hair growth treatments.
- Exosomes, a key product of the company, are body-identical ingredients known for their high stability and low likelihood of causing adverse reactions. Their cell-penetrating mechanism enables them to deliver regeneration signals, making them suitable for diverse medical and cosmetic applications.
- Has 3 major clients and supplied on a quarterly basis to pharmaceutical companies in Italy, Poland, and Brazil.
- Operates with a network of 12 agents in addition to its 3 permanent employees.
- Collaborates with Contract Manufacturing Organizations (CMOs) for the production of its pharmaceutical products.
The company holds essential regulatory licenses from GMP, FDA, and the Ministry of Health, ensuring compliance with international quality and safety standards.
- Has a portfolio of R&D projects and two Finished Dosage Forms (FDF) in the Italian market, including Aripiprazole and Emtricitabine + Tenofovir.
- The company specializes in the development of microfluidic technology for the production and purification of Exosomes, with applications in anti-inflammatory, skin regenerative, anti-acne and atopic dermatitis, scalp rejuvenation, and hair growth treatments.
- Exosomes, a key product of the company, are body-identical ingredients known for their high stability and low likelihood of causing adverse reactions. Their cell-penetrating mechanism enables them to deliver regeneration signals, making them suitable for diverse medical and cosmetic applications.
- Has 3 major clients and supplied on a quarterly basis to pharmaceutical companies in Italy, Poland, and Brazil.
- Operates with a network of 12 agents in addition to its 3 permanent employees.
- Collaborates with Contract Manufacturing Organizations (CMOs) for the production of its pharmaceutical products.
The company holds essential regulatory licenses from GMP, FDA, and the Ministry of Health, ensuring compliance with international quality and safety standards.
Products & Services Overview
Two Finished Dosage Forms (FDF) in the Italian market - Aripiprazole and Emtricitabine + Tenofovir.Used in cancer immuno personalized therapy.
Exosomes - used in anti-inflammatory, skin regenerative, anti-acne and atopic dermatitis, scalp rejuvenation, and hair growth treatments.
Supplied to pharmaceutical companies in Italy, Poland, and Brazil.
Assets Overview
Physical assets include cash deposits, inventory, office assets etc.Intangible assets include the R&D projects and pharma licence for two pharmaceutical products.
Facilities Overview
Currently operating from a rented office space in Corso Di Porta Vittoria, Milan.Production is through contract manufacturing.
Capitalization Overview
Business is self-funded.No outstanding loans.
There are two shareholders with an ownership split of 15% and 85%.
Two Products MA in Italy.
Recent Activity
-
Earlier than 15 daysCEO, BioTechnology, Frankfurt, Individual Investor / Buyer connected with the Business
-
Earlier than 15 daysOwner, Investment, Milan, Corporate Investor / Buyer connected with the Business
-
Earlier than 15 daysCEO, Life Sciences, Newton, Individual Investor / Buyer connected with the Business
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct. Note that SMERGERS is not liable for any loss, damage, costs, claims and expenses whatsoever arising from transacting with any other user from the website. The final responsibility of conducting a thorough due diligence and taking the transaction forward lies with the users. Please read best practices on SMERGERS.
Contact Business
9 Investors already contacted this Business.
Register below to connect now!
- Social
- Register
- Login
Who uses SMERGERS?
... and 116,500+ other businesses of all sizes.
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct.
You might also be interested in these businesses